Valiant Laboratories Ltd
Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]
- Market Cap ₹ 415 Cr.
- Current Price ₹ 95.5
- High / Low ₹ 168 / 75.2
- Stock P/E
- Book Value ₹ 53.3
- Dividend Yield 0.00 %
- ROCE -1.64 %
- ROE -1.71 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|
334 | 182 | 106 | |
299 | 190 | 119 | |
Operating Profit | 35 | -8 | -13 |
OPM % | 11% | -5% | -12% |
5 | 10 | 10 | |
Interest | 0 | 0 | 0 |
Depreciation | 2 | 2 | 2 |
Profit before tax | 38 | -1 | -5 |
Tax % | 24% | -142% | |
29 | 0 | -4 | |
EPS in Rs | 8.91 | 0.07 | -0.96 |
Dividend Payout % | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -56% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -144% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -40% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|
Equity Capital | 33 | 43 | 43 |
Reserves | 68 | 193 | 188 |
60 | 77 | 116 | |
52 | 29 | 14 | |
Total Liabilities | 213 | 343 | 361 |
48 | 50 | 49 | |
CWIP | 1 | 43 | 113 |
Investments | 34 | 38 | 4 |
130 | 212 | 195 | |
Total Assets | 213 | 343 | 361 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | |
---|---|---|
56 | 2 | |
-55 | -144 | |
-1 | 152 | |
Net Cash Flow | -0 | 10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2023 | Mar 2024 | |
---|---|---|
Debtor Days | 97 | 92 |
Inventory Days | 17 | 22 |
Days Payable | 62 | 56 |
Cash Conversion Cycle | 52 | 57 |
Working Capital Days | 71 | 109 |
ROCE % | -2% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Certificate under Regulation 74(5) for Q1 2025.
-
Closure of Trading Window
26 Mar - Closure of trading window until financial results declaration.
-
Announcement under Regulation 30 (LODR)-Credit Rating
19 Feb - CRISIL downgrades Valiant Laboratories' credit rating to BBB/Negative.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Feb - Newspaper Publication of the Financial Results for the quarter ended December 31, 2024.
-
Integrated Filing (Financial)
7 Feb - Integrated filing of financial results for Q4 2024.
Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever